Here are three GI companies that made headlines this week:
San Francisco-based Versant Ventures launched Jecure Therapeutics on Feb. 15, 2017. Jecure is a biotech company with a proprietary liver disease platform. To date, it has developed treatment programs for non-alcoholic steatohepatitis and fibrosis.
Japan-based Takeda acquired Cambridge, Mass.-based Ariad Pharmaceuticals for $24 per share. New York City-based law firm Faruqi & Faruqi previously investigated whether Ariad properly executed fair sale practices.
Laval, Canada-based Valeant’s move to sell $2.1 billion in assets in January 2017 positively impacted its debt pathway. Valeant can cover its August 2018 bond when it matures.
More articles on gastroenterology:
GI leader to know: Dr. Shahab Aftahi of Estrella Gastroenterology
Versant Ventures launches Jecure Therapeutics: 4 key notes
Study associates Barrett’s esophagus with early-stage GI cancers: 3 study insights
